Mrudula Munagala

Mrudula Munagala

Auto-generated profile, based on publicly available information

Mrudula Munagala


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2021
Verified
Book Chapter
Closed access
PDF file
MMMrudula Munagala
Mrudula Munagala
APAnita Phancao
Anita Phancao

7 October 2022 in Journal of Medical Internet Research
Verified
Journal Article
Open access
NMNell J Marshall
Nell J Marshall
JLJennifer L Lee
Jennifer L Lee
JSJessica Schroeder
Jessica Schroeder
WLWei-Nchih Lee
Wei-Nchih Lee
JSJermyn See
Jermyn See
SSSandrine Samson
Sandrine Samson
Background: Seasonal influenza affects 5% to 15% of Americans annually, resulting in preventable deaths and substantial economic impact. Influenza infection is particularly dangerous for people with cardiovascular disease, who therefore represent a priority group for vaccination campaigns. Objective: We aimed to assess the effects of digital intervention messaging on self-reported rates of seasonal influenza vaccination. Methods: This was a randomized, controlled, single-blind, and decentralized trial conducted at individual locations throughout the United States over the 2020-2021 influenza season. Adults with self-reported cardiovascular disease who were members of the Achievement mobile platform were randomized to receive or not receive a series of 6 patient-centered digital intervention messages promoting influenza vaccination. The primary end point was the between-group difference in self-reported vaccination rates at 6 months after randomization. Secondary outcomes included the levels of engagement with the messages and the relationship between vaccination rates and engagement with the messages. Subgroup analyses examined variation in intervention effects by race. Controlling for randomization group, we examined the impact of other predictors of vaccination status, including cardiovascular condition type, vaccine drivers or barriers, and vaccine knowledge. Results: Of the 49,138 randomized participants, responses on the primary end point were available for 11,237 (22.87%; 5575 in the intervention group and 5662 in the control group) participants. The vaccination rate was significantly higher in the intervention group (3418/5575, 61.31%) than the control group (3355/5662, 59.25%; relative risk 1.03, 95% CI 1.004-1.066; P=.03). Participants who were older, more educated, and White or Asian were more likely to report being vaccinated. The intervention was effective among White participants (P=.004) but not among people of color (P=.42). The vaccination rate was 13 percentage points higher among participants who completed all 6 intervention messages versus none, and at least 2 completed messages appeared to be needed for effectiveness. Participants who reported a diagnosis of COVID-19 were more likely to be vaccinated for influenza regardless of treatment assignment. Conclusions: This personalized, evidence-based digital intervention was effective in increasing vaccination rates in this population of high-risk people with cardiovascular disease. Trial Registration: ClinicalTrials.gov NCT04584645; https://clinicaltrials.gov/ct2/show/NCT04584645

7 December 2023 in Current Heart Failure Reports
Verified
Journal Article
Closed access
PDF file
RRRoopa A. Rao
Roopa A. Rao
ABAnju Bhardwaj
Anju Bhardwaj
MMMrudula Munagala
Mrudula Munagala
SASonu Abraham
Sonu Abraham
SASanjana Adig
Sanjana Adig
EHEman A. Hamad
Eman A. Hamad

1 October 2021 in Journal of Cardiac Surgery
Verified
Journal Article
Closed access
PDF file
JCJorge L. Cardenas‐Alvarez
Jorge L. Cardenas‐Alvarez
JSJose Suarez
Jose Suarez
GMGabriel Motoa
Gabriel Motoa
SAShweta Anjan
Shweta Anjan
YNYoichiro Natori
Yoichiro Natori
JSJacques Simkins
Jacques Simkins

19 August 2021 in Current Cardiology Reports
Verified
Journal Article
Closed access
PDF file
DKDevika Kir
Devika Kir
MPMausam J. Patel
Mausam J. Patel
MMMrudula R. Munagala
Mrudula R. Munagala

20 April 2022 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
DKDevika Kir
Devika Kir
MMMrudula Munagala
Mrudula Munagala
Heart failure through the spectrum of reduced (HFrEF), mid-range (or mildly reduced or HFmEF), and preserved ejection fraction (HFpEF), continues to plague patients' quality of life through recurrent admissions and high mortality rates. Despite tremendous innovation in medical therapy, patients continue to experience refractory congestive symptoms due to adverse left ventricular remodeling, significant functional mitral regurgitation (FMR), and right-sided failure symptoms due to significant functional tricuspid regurgitation (FTR). As most of these patients are surgically challenging for open cardiac surgery, the past decade has seen the development and evolution of different percutaneous structural interventions targeted at improving FMR and FTR. There is renewed interest in the sphere of left ventricular restorative devices to effect reverse remodeling and thereby improve effective stroke volume and patient outcomes. For patients suffering from HFpEF, there is still a paucity of disease-modifying effective medical therapies, and these patients continue to have recurrent heart failure exacerbations due to impaired left ventricular relaxation and high filling pressures. Structural therapies involving the implantation of inter-atrial shunt devices to decrease left atrial pressure and the development of implantable devices in the pulmonary artery for real-time hemodynamic monitoring would help redefine treatment and outcomes for patients with HFpEF. Lastly, there is pre-clinical data supportive of soft robotic cardiac sleeves that serve to improve cardiac function, can assist contraction as well as relaxation of the heart, and have the potential to be customized for each patient. In this review, we focus on the role of structural interventions in heart failure as it stands in current clinical practice, evaluate the evidence amassed so far, and review promising structural therapies that may transform the future of heart failure management.